Clinical-stage company IRX Therapeutics has appointed Luba Greenwood to its board of directors.
Her career has seen her gain significant pharmaceutical and biotechnology industry expertise, including building technology companies and providing strategic counsel to corporations.
Mark Leuchtenberger, president and chief executive officer, IRX Therapeutics, said: “Luba is a proven and respected leader in the life science sector.
“She has excelled as an investor, business development professional, lawyer and corporate strategist.”
Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations.
Greenwood most recently served as venture partner at Colt Ventures, and led business development strategy for Pronutria.
Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.
She said: “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumour microenvironment with IRX-2.”